PeptideBase
Back to Database
evidence varies by claim

Edotreotide

Edotreotide

Cancer & Peptide Vaccines

Edotreotide is indexed as peptide radioligand/therapeutic in the PeptideBase article library. It is referenced in “Peptides in Real Medicine: PRRT, Edotreotide, and Neuroendocrine Tumor Evidence”. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.

Research status: evidence varies by claim

Deep Dives on Edotreotide

Start here for the plain-English articles connected to this peptide.

evidence-literacy10 min read

Peptides in Real Medicine: PRRT, Edotreotide, and Neuroendocrine Tumor Evidence

What the phase 3 COMPETE trial of [177Lu]Lu-edotreotide versus everolimus teaches about peptide receptor radionuclide therapy, disease-specific evidence, and why regulated peptide medicines should not be confused with wellness peptide marketing.

Read article

Quick Facts

Origin
Named peptide radioligand/therapeutic referenced in PeptideBase coverage
Category
Cancer & Peptide Vaccines

Research Areas

evidence-literacy

Tags

edotreotide177lu-edotreotidelu-edotreotideitm-11peptide radioligand/therapeuticnamed peptide